User login
Key clinical point: Male patients who survived breast cancer (BC) were more likely to develop second primary cancers (SPC), such as colorectal, pancreatic, and thyroid cancers.
Major finding: Standardized incidence ratio (SIR) of any SPC was estimated to be 1.27 (95% CI 1.03-1.56), with the risk being elevated in the case of a second primary colorectal cancer (SIR 1.29; 95% CI 1.03-1.61), pancreatic cancer (SIR 1.64; 95% CI 1.05-2.55), and thyroid cancer (SIR 5.58; 95% CI 1.04-30.05).
Study details: Findings are from a meta-analysis of eight retrospective cohort studies including male BC survivors.
Disclosures: This study was funded by the Cancer Research UK Catalyst Award CanGene-CanVar. The authors declared no conflicts of interest.
Source: Allen I et al. Risk of developing a second primary cancer in male breast cancer survivors: A systematic review and meta-analysis. Br J Cancer. 2022;127:1660–1669 (Sep 17). Doi: 10.1038/s41416-022-01940-1
Key clinical point: Male patients who survived breast cancer (BC) were more likely to develop second primary cancers (SPC), such as colorectal, pancreatic, and thyroid cancers.
Major finding: Standardized incidence ratio (SIR) of any SPC was estimated to be 1.27 (95% CI 1.03-1.56), with the risk being elevated in the case of a second primary colorectal cancer (SIR 1.29; 95% CI 1.03-1.61), pancreatic cancer (SIR 1.64; 95% CI 1.05-2.55), and thyroid cancer (SIR 5.58; 95% CI 1.04-30.05).
Study details: Findings are from a meta-analysis of eight retrospective cohort studies including male BC survivors.
Disclosures: This study was funded by the Cancer Research UK Catalyst Award CanGene-CanVar. The authors declared no conflicts of interest.
Source: Allen I et al. Risk of developing a second primary cancer in male breast cancer survivors: A systematic review and meta-analysis. Br J Cancer. 2022;127:1660–1669 (Sep 17). Doi: 10.1038/s41416-022-01940-1
Key clinical point: Male patients who survived breast cancer (BC) were more likely to develop second primary cancers (SPC), such as colorectal, pancreatic, and thyroid cancers.
Major finding: Standardized incidence ratio (SIR) of any SPC was estimated to be 1.27 (95% CI 1.03-1.56), with the risk being elevated in the case of a second primary colorectal cancer (SIR 1.29; 95% CI 1.03-1.61), pancreatic cancer (SIR 1.64; 95% CI 1.05-2.55), and thyroid cancer (SIR 5.58; 95% CI 1.04-30.05).
Study details: Findings are from a meta-analysis of eight retrospective cohort studies including male BC survivors.
Disclosures: This study was funded by the Cancer Research UK Catalyst Award CanGene-CanVar. The authors declared no conflicts of interest.
Source: Allen I et al. Risk of developing a second primary cancer in male breast cancer survivors: A systematic review and meta-analysis. Br J Cancer. 2022;127:1660–1669 (Sep 17). Doi: 10.1038/s41416-022-01940-1